Alunbrig (brigatinib)

pCPA File Number: 21467
Negotiation Status:
Under consideration for negotiation
Indication(s):
naplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer; adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC previously untreated with an ALK inhibitor
Sponsor/Manufacturer:
Takeda Canada Inc.
CADTH Project Number:
PC0230-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable